A

Arlington Dermatology | Rolling Meadows, IL

Research site
(Unclaimed)
Location
5301 Keystone Court, Rolling Meadows, Illinois, United States of America

Site insights

Top conditions

Top treatments

JNJ-77242113
Risankizumab
TAK-279
Guselkumab
Ruxolitinib

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 13 total trials

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque p...

Enrolling
Plaque Psoriasis
Drug: TAK-279
Drug: Apremilast

The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deu...

Enrolling
Plaque Psoriasis
Drug: Deucravacitinib Matching Placebo
Drug: JNJ-77242113

The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo an...

Enrolling
Plaque Psoriasis
Drug: Deucravacitinib Matching Placebo
Drug: JNJ-77242113 Matching Placebo

The purpose of the study is to see how effective JNJ-77242113 is in participants with plaque psoriasis affecting special areas (scalp, genital, and/o...

Active, not recruiting
Plaque Psoriasis
Drug: JNJ-77242113
Drug: Placebo

The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.

Active, not recruiting
Plaque Psoriasis
Drug: JNJ-77242113
Drug: Placebo
Locations recently updated

This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or a...

Enrolling
Atopic Dermatitis
Drug: Ruxolitinib Cream
Drug: Vehicle Cream

The purpose of this study is to evaluate the efficacy and safety of guselkumab in pediatric participants aged greater than or equal to 6 through less...

Active, not recruiting
Psoriasis
Drug: Etanercept
Drug: Placebo for guselkumab
Locations recently updated

Psoriasis is a long-term skin disease which causes red, itchy, scaly patches most commonly on the knees, elbows, scalp, and torso (chest, back, and a...

Enrolling
Moderate Plaque Psoriasis
Drug: Risankizumab
Drug: Deucravacitinib

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

The purpose of this study is to determine the efficacy and safety of a monoclonal antibody, OpSCF, in the treatment of adults with moderate to severe...

Active, not recruiting
Atopic Dermatitis
Biological: OpSCF
Biological: Placebo

Psoriasis (PsO) is a chronic disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques. This study will asse...

Enrolling
Scalp Psoriasis
Genital Psoriasis
Drug: Risankizumab
Drug: Placebo for Risankizumab

Trial sponsors

J
AbbVie logo
Incyte logo
Lilly logo
O
Takeda logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems